WO1992016181A2 - Composition for promoting tissue repair and regeneration - Google Patents
Composition for promoting tissue repair and regeneration Download PDFInfo
- Publication number
- WO1992016181A2 WO1992016181A2 PCT/US1992/002043 US9202043W WO9216181A2 WO 1992016181 A2 WO1992016181 A2 WO 1992016181A2 US 9202043 W US9202043 W US 9202043W WO 9216181 A2 WO9216181 A2 WO 9216181A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pdgf
- dexamethasone
- tissue
- regeneration
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- Polypeptide growth factors are a class of natural biological mediators that regulate the proliferation, differentiation, motility and matrix synthesis of nearly all cell types. These properties, demonstrable in vivo, have led to the proposal that such factors play important roles in soft and hard tissue repair.
- Platelet-derived growth factor (PDGF) is a well characterized example of such a polypeptide growth factor.
- PDGF is a peptide hormone produced by blood platelets which influences the regulation of a broad array of biological systems including wound repair, arteriosclerosis, neoplasia, embryogenesis and bone marrow fibrosis.
- PDGF is a mitogen, that is, a substance which induces mitosis of cells and thus cellular proliferation.
- PDGF elicits both chemotactic and mitogenic responses in fibroblasts, smooth muscle, glial cells, etc.
- Injury to the endothelium lining the vessel wall is believed to cause platelets to adhere to exposed connective tissue at the wound site, with the concomitant release of PDGF.
- the released PDGF is thought to chemotactically recruit many cell types including fibroblasts, monocytes, glial and smooth muscle to migrate into the site of the wound. Increased proliferation of these cells leads to accelerated tissue regeneration and wound healing.
- dexamethasone acts synergistically with cartilage-derived growth factor (CDGF) to enhance the stimulation of DNA synthesis in quiescent Swiss 3T3 cells, while having only a neutral effect with PDGF.
- CDGF cartilage-derived growth factor
- Levenson et al. showed that the addition of dexamethasone to PDGF-stimulated cultures had no effect on DNA synthesis over that observed with PDGF alone.
- the present invention relates to a method for enhancing tissue regeneration and/or wound repair in a mammal comprising applying to the tissue or wound an effective amount of a composition comprising an anti- inflammatory compound and PDGF.
- the method promotes cellular activity at the site of the wound which expedites healing of the wound.
- the combination of PDGF and anti-inflammatory compound synergistically promotes the proliferation of mammalian cells at the site.
- Either natural-sourced or recombinant PDGF can be used in the composition.
- many anti- inflammatory agents can synergistically enhance the mitogenic effect of PDGF on cells.
- Anti-inflammatory agents which are particularly useful are a class of compounds known as glucocorticoids. Glucocorticoids include cortisone, hydrocortisone (cortisol), dexamethasone, and pharmacologically active derivatives thereof, for example.
- the method of the present invention can be used to promote tissue regeneration and/or wound healing in a variety of tissues.
- the method is effective for enhancing tissue regeneration and wound healing in epithelial tissues, and for promoting regeneration of bone and/or cartilage tissues.
- applying the composition to an area where epithelium, bone or cartilage has been broken, torn or eroded due to injury or disease for example, stimulates the regeneration and repair of the epithelium, bone or cartilage.
- the method is particularly effective for treating tissues affected by periodontal disease.
- the method is carried out by applying a composition of PDGF and the anti-inflammatory compound to the affected gum tissue and periodontal ligament.
- the composition promotes regeneration of the gum tissue, of tooth tissues such as dentin and pulp, and of the connective tissue holding the tooth in place in the gum.
- the present method provides an effective therapeutic composition for treating external wounds, including skin ulcers, burns and lesions and for regenerating connective tissue and/or bone.
- the method is particularly effective for treating dental tissue affected by periodontal disease.
- Figure 1 is a graph showing the influence of dexamethasone on the mitogenic activity of both PDGF alone and PDGF + IGF-1.
- Figure 2 is a graph showing the effect on cell population density of various concentrations of dexamethasone an PDGF + IGF-1.
- Figure 3 is a graph showing the influence of dexamethasone on the mitogenic activity of PDGF using PDGF + IGF-1 as control reference.
- Figure 4 is a graph comparing the mitogenic activity of PDGF- ⁇ and PDGF- ⁇ .
- the present method comprises applying a combination of PDGF and an anti-inflammatory compound to a tissue.
- Native PDGF is a dimeric molecule comprised of two polypeptide chains, one or more of which may be glycosylated.
- the two chains (referred to as alpha ( ⁇ ), and beta ( ⁇ )) are homologous but not identical.
- the ⁇ chain has a molecular weight of about 17,000 to 18,000 and the ⁇ chain has a molecular weight of about 13,000 to 14,000.
- the ⁇ and ⁇ chains are synthesized in vivo from larger molecules which are subsequently processed at the amino and carboxyl- termini.
- the mature human ⁇ chain is comprised of 110 or 125 amino acids and various N-linked sugar side chains, and the length and amino acid sequence is dependent on the tissue source.
- the fully processed human ⁇ chain is encoded by the c-sis gene and is comprised of 112 amino acids.
- Biologically active PDGF can exist as a homodimer e.g., ⁇ , ⁇ , or a heterodiminer ⁇ .
- the molecular weights of the ⁇ homodimer and ⁇ homodimer are about 35,000 and about 32,000, respectively.
- PDGF useful in the present invention may be natural sourced, recombinant or synthetic PDGF.
- Natural sourced can be extracted from human platelets, for example as described by Popen et al. (1979) Proc. Natl. Acad. Sci. USA, 7_6_:3722-33726; Antoniades et al. (1979) Proc. Natl. Acad. Sci. USA, 7_6:1809-1813, Antoniades et al., U.S. Patent No. 4,479,896; and Lipton et al. ; U.S. Patent No. 4,350,687.
- Recombinant PDGF can be produced using transformed eucaryotic cells, such as yeast, (See, EP Publication No.
- PDGF also can be synthesized using art-recognized peptide synthesis techniques. Biologically active fragments. derivatives or mutant forms of PDGF can be used in the present invention.
- PDGF which can be used is commercially available, for example, from Amgen Corporation, Thousand Oaks, California; PDGF Inc., Boston, Massachusetts; Collaborative Research Inc., Waltham, Massachusetts; and Creative BioMolecules, Inc., Hopkinton, Massachusetts.
- Anti-inflammatory compounds are compounds which reduce inflammation by acting on body mechanics without directly antagonizing the causative agent.
- a class of anti-inflammatory compounds which is particularly useful in the present method comprises glucocorticoids.
- Glucocorticoids include, for example, cortisone, hydrocortisone (cortisol), dexamethasone and pharmacologically active derivatives of these drugs, e.g., hydrocortisone acetate.
- Dexamethasone and cortisol are commercially available from a number of sources, for example, Sigma Chemical Co., Saint Louis, Missouri. Wound healing and tissue regeneration can be promoted by directly, locally applying an effective amount of a composition comprising PDGF and the selected anti-inflammatory compound to the affected tissue.
- the tissue can be external epithelial tissue, internal epithelial tissue, bone, cartilage, or dental tissue, including gum tissue, dentin, pulp, ceraentum or periodontal ligature.
- the concentration of PDGF and of the anti- inflammatory compound will depend in part upon the compound selected, its potency and the tissue it is applied to. The amount can be determined empirically by applying a low dose and observing the effects and incrementally increasing the dose until the desired effect is obtained.
- a concentration of PDGF of from about 0.1 ⁇ g/ml to about 10 mg/ml is effective for most applications.
- a concentration of from about 10 " 5 M to about 10 " 12 M can be used.
- a concentration of from about 10 " 5 M to about 10 "12 M of dexamethasone has been shown to significantly enhance the activity to PDGF.
- a concentration of about 10 "5 to about 10 " 9 M is most preferred.
- TGF- ⁇ transforming growth factor- ⁇
- IGF-1 insulin-like growth factors
- IGF-1 or other growth factor can be added to the PDGF mixture in a weight-to-weight ratio, for example, of about 1:4 and 25:1, preferably between about 1:2 and 10:1, and more preferably 1:1 or 2:1.
- a pharmaceutically acceptable carrier substance for local, topical administration.
- pharmaceutically acceptable carriers include, for example, commercially available inert gels, or liquids supplemented with albumin, methyl cellulose or a collagen matrix. Typical of such formulations are ointments, creams and gels.
- Ointments are typically prepared using an oleaginous base, e.g., containing fixed oils or hydrocarbons, such as white petrolatum or mineral oil, or an absorbent base, e.g., consisting of an absorbent anhydrous substance or substances, for example, anhydrous lanolin. Following formation of the base, the active ingredients are added in the desired concentration.
- Creams generally comprise an oil phase (internal phase) containing typically fixed oils, hydrocarbons, and the like, such as waxes, petrolatum, mineral oil, and the like, and an aqueous phase (continuous phase), comprising water and any water-soluble substances, such as added salts.
- an emulsifying agent for example, a surface active agent, such as sodium laurul sulfate; hydrophilic colloids, such as acacia colloidal clays, beegum, and the like.
- a surface active agent such as sodium laurul sulfate
- hydrophilic colloids such as acacia colloidal clays, beegum, and the like.
- the active ingredients are added in the desired concentration.
- Gels are comprised of a base selected from an oleaginous base, water, or an emulsion-suspension base, as previously described.
- a gelling agent which forms a matrix in the base, increasing its viscosity to a semisolid consistency. Examples of gelling agents are hydroxypropyl cellulose, acrylic acid polymers, and the like.
- the active ingredients are added to the formulation at the desired concentration at a point preceding addition of the gelling agent.
- a typical gel formulation useful for the topical administration of PDGF and dexamethasone comprises the following: % by Weight sterile distilled water 92.38 sodium dibasic phosphate 0.03 CarbapolTM 0.5 glycerin 1.6 m-cresol 0.25 sodium hydroxide (IN) 0.5
- a bone collagen matrix as described in U.S. Patent No. 4,975,526, which is incorporated herein by reference, can be used as the carrier for application to bone and/or cartilage.
- the collagen matrix described in this patent is a biodegradable, biocompatible, mineral-free, insoluble Type-I bone collagen particles being depleted of non-collagenous protein.
- the collagen matrix particles have a mean diameter of about 70 ⁇ m - 850 ⁇ m, and an increased intraparticle surface area relative to untreated material.
- PDGF and the anti- inflammatory agent are first dissolved in a suitable solvent such as buffered sterile saline and then added to the collagen matrix. The mixture is vortexed, and the matrix is lyophilized and shaped as desired or implanted into an area of bone or cartilage by packing.
- matrix materials include synthetic homopolymers and copolymers of glycolic acid and lactic acid, hydr ⁇ xyapatite, tricalcium and other calcium phosphates, and particulate demineralized guanidine extracted species-specific (allogenic) bone.
- the matrix containing the PDGF and steroid can be applied into a shape spanning the bone or cartilage defect to serve as a "temporary scaffold" and substratum as a base for anchoring and proliferation of differentiated tissue cells.
- the method is particularly useful for treating tissues affected by periodontal disease.
- Periodontal disease is characterized by gingivitis, destruction of alveolar bone and periodontal ligament, apical migration of the epithelial attachment resulting in the formation of periodontal pockets.
- a number of different tissues are involved, including epithelium, cartilage and bone.
- the method of the invention promotes healing and regeneration of the gum tissues (epithial tissue) the periodontal ligament (cartilage) and the jaw bone (bone). Pulp and dentin tissue within the tooth which was eroded or attacked by periodontal disease can be regenerated using the present method.
- the most preferred composition for this purpose is a combination of PDGF and dexamethasone.
- PDGF mitogenesis is enhanced in the presence of a glucocorticoid.
- Current methodologies described in the literature disclose the use of PDGF as an agent to enhance tissue repair or reduce regeneration jln vivo utilizing another human growth factor, IGF-1 in combination with PDGF. This is substantially more expensive and less effective than using the small amounts (e.g., less than 10 " 5 M) of glucocorticoid drugs, as described herein.
- the glucocorticoids have anti-inflammatory properties, which are beneficial where inflammation is present, such as with many periodontal diseases.
- glucocorticoid drug in a preferred concentration of from about 10 " 7 M to about 10 " 9 M was consistently more effective than adding l ⁇ g/ml IFG-1 for enhancing the cell proliferation which is the basis of tissue regeneration and repair.
- Example 1 Potentiation of mitogenic effect of PDGF and IGF-1 by Dexamethasone
- the following experiments were all performed on low passage, human diploid fibroblasts obtained from the periodontal ligaments and dental pulps of extracted teeth.
- the cells were cultured under standard culture conditions and stocks were propagated with 10% fetal bovine serum (FBS) as the source of growth factors.
- FBS fetal bovine serum
- the cells were plated at 10,000 to 15,000 cells per 1.88 cm 2 of surface area in 24 well culture plates and conditioned in medium containing 0.1% FBS for 24-48 hours prior to treatment. The cells were then exposed once to the indicated concentrations of PDGF, IGF-1 and/or dexamethasone in culture media at time zero.
- the cells were quantitatively harvested from each well and the total cell population densities were determined using a Coulter counter by standard methods.
- the PDGF- ⁇ and PDGF- ⁇ used in these studies were recombinant human analogs of PDGF produced in E_. coli which were provided by Creative BioMolecules, Hopkinton, Massachusetts.
- the dexamethasone was purchased from Sigma Chemical Company, St. Louis, Missouri.
- Plate 3 contained PDGF- ⁇ 200 ng/ l + 1GF-1 200 ng/ml
- Plate 4 contained PDGF- ⁇ 200 ng/ml + 1GF-1 200 ng/ml + 10 " M Dexamethasone
- Plate 5 contained PDGF- ⁇ 200 ng/ml + 1GF-1 200 ng/ml + 10 " M Dexamethasone
- Plate 8 contained PDGF- ⁇ 200 ng/ml + 1GF-1 200 ng/ml + 10 "10 M Dexamethasone
- Plate 9 contained PDGF- ⁇ 200 ng/ml + 1GF-1 200 ng/ml + 10 _11 M Dexamethasone
- Plate 10 contained PDGF- ⁇ 200 ng/ml + 1GF-1 200 ng/ml + 10 "12 M Dexamethasone
- Plate 11 contained PDGF- ⁇ 200 ng/ml + 10 " 7 M Dexamethasone Plate 12 contained PDGF- ⁇ 200 ng/ml
- Figure 1 shows that cultures treated with dexamethasone in combination with PDGF proliferated faster than cultures treated with PDGF alone and PDGF + IGF-1.
- Figure 2 shows that dexamethasone is effective in enhancing all proliferation over concentrations ranging from 10 " 5 to 10 _11 M.
- the concentration of dexamethasone to optimally potentiate the mitogenic activity of PDGF at 200 ng/ml is about 10 " 7 M.
- the mitogenic activity of the cells was increased by the combination of dexamethasone and PDGF more than by just PDGF alone or PDGF + IGF-1. However, there was no further enhancement of mitogenic activities by the addition of IGF-1 to PDGF and dexamethasone.
- Example 2 Comparison of the effects on mitogenic activity of dexamethasone with IGF-1 over time. To determine the time course of the effects of dexamethasone on PDGF- ⁇ mitogenic activity, cultures were treated with PDGF + IGF-1 and PDGF with and without dexamethasone at 10 " 7 and 10 "12 M, harvested and counted at the time indicated over a period of 160 hours. Data from the same experiment are plotted against the controls in two separate plots for clarity. The results, shown in Figure 3, revealed that a single exposure of the cultured cells at time zero to PDGF- ⁇ plus dexamethasone resulted in final increased cell population densities after 160 hours that were similar to those obtained by exposure of the cultured cells to PDGF- ⁇ plus IGF-1.
- the final total cell number was similar for treatment with 10 ng/ml and 500 ng/ml PDGF- ⁇ .
- the PDGF- ⁇ + IGF-1 treated cultures reached maximal cell population densities at 96 hours, while those exposed to PDGF- ⁇ + dexamethasone had not plateaued by 160 hours, demonstrating the prolonged effect of a single dose of PDGF + dexamethasone on cell proliferation.
- Example 3 Comparison of the Mitogenic Activity of PDGF- ⁇ and PDGF- ⁇ .
- Plates prepared as described above were treated with PDGF- ⁇ or PDGF- ⁇ and dexamethasone or IGF-1. The extent of cell growth determined.
- Plate 1 contained 0.1% FBS + 10 " 7 M dexamethasone.
- Plate 2 contained PDGF- ⁇ 500 ng/ml.
- Plate 3 contained PDGF- ⁇ 500 ng/ml + IGF-1 500 ng/ml.
- Plate 4 contained PDGF- ⁇ 500 ng/ml + 10 " 5 M dexamethasone.
- PDGF- ⁇ Studies 5 contained 0.1% FBS _ 10 " 7 dexamethasone.
- Plate 6 contained PDGF- ⁇ 500 ng/ml.
- Plate 7 contained PDGF- ⁇ 500 ng/ml + IGF-1 500 ng/ml.
- P PIlate 8 contained PDGF- ⁇ 500 ng/ml + 10 " 7 M dexamethasone.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002106073A CA2106073C (en) | 1991-03-12 | 1992-03-12 | Composition for promoting tissue repair and regeneration |
AT92908042T ATE196604T1 (en) | 1991-03-12 | 1992-03-12 | COMPOSITION CONTAINING PDGF AND DEXAMETHASON FOR PROMOTING TISSUE REPAIR AND REGENERATION |
DE69231486T DE69231486T2 (en) | 1991-03-12 | 1992-03-12 | COMPOSITION CONTAINING PDGF AND DEXAMETHASONE TO PROMOTE TISSUE REPAIR AND REGENERATION |
JP4507585A JPH07505858A (en) | 1991-03-12 | 1992-03-12 | Methods for promoting tissue repair and regeneration |
AU15591/92A AU656372B2 (en) | 1991-03-12 | 1992-03-12 | Composition for promoting tissue repair and regeneration |
EP92908042A EP0575484B1 (en) | 1991-03-12 | 1992-03-12 | Composition comprising pdgf and dexamethasone for promoting tissue repair and regeneration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/669,070 US5149691A (en) | 1991-03-12 | 1991-03-12 | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
US669,070 | 1991-03-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1992016181A2 true WO1992016181A2 (en) | 1992-10-01 |
WO1992016181A3 WO1992016181A3 (en) | 1992-11-12 |
Family
ID=24684879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/002043 WO1992016181A2 (en) | 1991-03-12 | 1992-03-12 | Composition for promoting tissue repair and regeneration |
Country Status (8)
Country | Link |
---|---|
US (2) | US5149691A (en) |
EP (1) | EP0575484B1 (en) |
JP (1) | JPH07505858A (en) |
AT (1) | ATE196604T1 (en) |
AU (1) | AU656372B2 (en) |
CA (1) | CA2106073C (en) |
DE (1) | DE69231486T2 (en) |
WO (1) | WO1992016181A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997045533A1 (en) * | 1996-05-28 | 1997-12-04 | The Regents Of The University Of Michigan | Engineering oral tissues |
WO2003037356A1 (en) * | 2001-10-26 | 2003-05-08 | Fresenius Kabi Deutschland Gmbh | Pharmaceutical preparation comprising a growth factor and/or a cytokine and an antiseptic biguanide |
US7847087B2 (en) | 2001-03-05 | 2010-12-07 | Siemens Healthcare Diagnostics Inc. | Methods and primers for evaluating HIV-1 mutations |
US8870954B2 (en) | 2008-09-09 | 2014-10-28 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
US9545377B2 (en) | 2004-10-14 | 2017-01-17 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
US9642891B2 (en) | 2006-06-30 | 2017-05-09 | Biomimetic Therapeutics, Llc | Compositions and methods for treating rotator cuff injuries |
US10258566B2 (en) | 2004-10-14 | 2019-04-16 | Biomimetic Therapeutics, Llc | Compositions and methods for treating bone |
US11235030B2 (en) | 2010-02-22 | 2022-02-01 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149691A (en) * | 1991-03-12 | 1992-09-22 | Creative Biomolecules, Inc. | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
US5770209A (en) * | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
US5837258A (en) | 1991-08-30 | 1998-11-17 | University Of South Florida | Induction of tissue, bone or cartilage formation using connective tissue growth factor |
US7384634B2 (en) * | 1991-08-30 | 2008-06-10 | University Of South Florida | Connective tissue growth factor |
US5408040A (en) * | 1991-08-30 | 1995-04-18 | University Of South Florida | Connective tissue growth factor(CTGF) |
US5444151A (en) * | 1992-05-15 | 1995-08-22 | Ludwig Institute For Cancer Research | Platelet derived growth factor antagonists |
US5326695A (en) * | 1992-05-15 | 1994-07-05 | Ludwig Institute For Cancer Research | Platelet derived growth factor agonists |
DE4228457A1 (en) * | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Production of heterodimeric PDGF-AB using a bicistronic vector system in mammalian cells |
US5455041A (en) * | 1993-09-13 | 1995-10-03 | Research Foundation Of State University Of New York At Buffalo | Method for inducing periodontal tissue regeneration |
US5942496A (en) * | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
EP0743066A3 (en) * | 1995-05-16 | 1998-09-30 | Mitsui Pharmaceuticals, Inc. | Wound-healing agent |
US6902584B2 (en) | 1995-10-16 | 2005-06-07 | Depuy Spine, Inc. | Bone grafting matrix |
US5776193A (en) | 1995-10-16 | 1998-07-07 | Orquest, Inc. | Bone grafting matrix |
DE19754140A1 (en) * | 1997-12-05 | 1999-06-24 | Era Beschichtung Gmbh & Co Kg | Interior material based on plastic, process for its production and use |
WO1999066797A1 (en) | 1998-06-22 | 1999-12-29 | Worden Charles E | Enriched platelet wound healant |
AU1430601A (en) * | 1999-11-02 | 2001-05-14 | Eli Lilly And Company | Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders |
EP1531837A4 (en) * | 2001-06-07 | 2006-11-15 | Chiou Consulting Inc | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
US7819888B2 (en) * | 2001-10-23 | 2010-10-26 | Innovasive Devices, Inc. | Method and apparatus for harvesting and implanting bone plugs |
EP1507543A4 (en) | 2002-05-09 | 2006-07-26 | Cambridgemed Inc | A pharmaceutical composition for treatment of wounds containing blood plasma or serum |
US20040018220A1 (en) * | 2002-07-26 | 2004-01-29 | Chiou Consulting, Inc. | Aqueous compositions for facial cosmetics |
US6616923B1 (en) * | 2002-07-26 | 2003-09-09 | Chiou Consulting, Inc. | Aqueous compositions for facial cosmetics |
ATE510605T1 (en) | 2003-03-14 | 2011-06-15 | Univ Columbia | SYSTEMS AND METHODS FOR BLOOD BASED THERAPY USING A MEMBRANELESS MICROFLUID EXCHANGE DEVICE |
US20060076295A1 (en) | 2004-03-15 | 2006-04-13 | The Trustees Of Columbia University In The City Of New York | Systems and methods of blood-based therapies having a microfluidic membraneless exchange device |
US7309232B2 (en) * | 2003-10-10 | 2007-12-18 | Dentigenix Inc. | Methods for treating dental conditions using tissue scaffolds |
US7258875B2 (en) * | 2003-12-04 | 2007-08-21 | Chiou Consulting, Inc. | Compositions and methods for topical treatment of skin infection |
US8293890B2 (en) * | 2004-04-30 | 2012-10-23 | Advanced Cardiovascular Systems, Inc. | Hyaluronic acid based copolymers |
GB0414803D0 (en) * | 2004-07-01 | 2004-08-04 | Glaxo Group Ltd | Composition |
US20060115266A1 (en) * | 2004-12-01 | 2006-06-01 | Gil Levi | All-optical protection signaling systems and methods in optical communication networks |
WO2007016620A2 (en) | 2005-08-01 | 2007-02-08 | Genera Doo | Methods and compositions for regenerating articular cartilage |
KR20080084808A (en) | 2005-11-17 | 2008-09-19 | 바이오미메틱 세라퓨틱스, 인크. | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
EP1976864B1 (en) | 2006-01-23 | 2012-09-26 | Imagene Co., Ltd. | Novel peptide and use thereof |
CN101534917A (en) | 2006-05-22 | 2009-09-16 | 纽约市哥伦比亚大学理事会 | Systems and methods of microfluidic membraneless exchange using filtration of extraction fluid outlet streams |
AU2013203287B2 (en) * | 2006-11-03 | 2015-12-17 | Biomimetic Therapeutics, Llc. | Compositions and methods for arthrodetic procedures |
EP2462895B1 (en) | 2006-11-03 | 2016-11-02 | BioMimetic Therapeutics, LLC | Compositions and methods for arthrodetic procedures |
US9511076B2 (en) * | 2008-05-30 | 2016-12-06 | Clarion Research Group | Formulations and methods for recovery from dental surgery |
US8282963B2 (en) * | 2007-10-15 | 2012-10-09 | The Regents Of The University Of Colorado, A Body Corporate | Methods for extracting platelets and compositions obtained therefrom |
ES2543254T3 (en) | 2008-01-07 | 2015-08-17 | Rapid Pathogen Screening, Inc. | Use of peptides to stimulate wound healing |
MX2010008591A (en) | 2008-02-04 | 2010-08-30 | Univ Columbia | Fluid separation devices, systems and methods. |
CN102014977B (en) | 2008-02-07 | 2015-09-02 | 生物模拟治疗有限责任公司 | For compositions and the method for Distraction Osteogenesis |
EP2403508B1 (en) * | 2009-03-06 | 2015-10-28 | Université Paris Descartes | Method of treating cancer employing gingival fibroblast conditioned medium |
JP2013536158A (en) | 2010-06-14 | 2013-09-19 | ジーン シグナル インターナショナル ソシエテ アノニム | Novel peptides for wound healing |
EP2395015B1 (en) | 2010-06-14 | 2013-03-06 | Gene Signal International SA | Peptides for wound healing |
US8288334B2 (en) | 2010-06-14 | 2012-10-16 | Gene Signal International Sa | Peptides for wound healing |
EP2593126B1 (en) | 2010-07-12 | 2017-09-20 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases |
US20130108683A1 (en) * | 2011-10-25 | 2013-05-02 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating partial and full thickness wounds and injuries |
KR20140123571A (en) | 2012-02-16 | 2014-10-22 | 에이티와이알 파마, 인코포레이티드 | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
JP6397479B2 (en) | 2013-03-15 | 2018-09-26 | エータイアー ファーマ, インコーポレイテッド | Histidyl-tRNA synthetase Fc conjugate |
MX2017004520A (en) | 2014-10-14 | 2018-03-15 | Lynch Samuel | Compositions for treating wounds. |
US11767520B2 (en) | 2017-04-20 | 2023-09-26 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
KR20200060997A (en) | 2018-11-23 | 2020-06-02 | (주)메디코스바이오텍 | Pharmaceutical Composition for Treatment of Wounds |
CZ308845B6 (en) | 2019-01-21 | 2021-07-07 | Globetech Innovation S.R.O | Pharmaceutical composition of topically healing peptide components for use in the topical treatment of skin defects and / or for topical wound healing |
PL433169A1 (en) | 2020-03-06 | 2021-09-13 | Gdański Uniwersytet Medyczny | Lipopeptide conjugates and their salts, method for the preparation thereof, pharmaceutical composition containing a lipopeptide conjugate and its salts for the treatment of chronic wounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0134385A2 (en) * | 1983-06-30 | 1985-03-20 | Sanwa Kagaku Kenkyusho Co., Ltd. | A protein having cell growth stimulating action, composition thereof and method for producing the same |
WO1988004180A1 (en) * | 1986-12-11 | 1988-06-16 | National Research Development Corporation | Improvements in or relating to the use of epidermal growth factor |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4957742A (en) * | 1984-11-29 | 1990-09-18 | Regents Of The University Of Minnesota | Method for promoting hair growth |
CA1322714C (en) * | 1986-11-14 | 1993-10-05 | Harry N. Antoniades | Wound healing and bone regeneration |
US5124316A (en) * | 1986-11-14 | 1992-06-23 | President And Fellows Of Harvard College | Method for periodontal regeneration |
US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
US4874746A (en) * | 1987-12-22 | 1989-10-17 | Institute Of Molecular Biology, Inc. | Wound headling composition of TGF-alpha and PDGF |
AU657472B2 (en) * | 1990-03-06 | 1995-03-16 | Claude Paul Genero | Towel or blanket support device |
US5149691A (en) * | 1991-03-12 | 1992-09-22 | Creative Biomolecules, Inc. | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
JPH06506939A (en) * | 1991-04-12 | 1994-08-04 | クリエイティブ バイオモレキュルズ インコーポレイテッド | Treatment method for gastrointestinal ulcers using platelet-derived growth factors |
-
1991
- 1991-03-12 US US07/669,070 patent/US5149691A/en not_active Expired - Fee Related
-
1992
- 1992-03-12 AT AT92908042T patent/ATE196604T1/en not_active IP Right Cessation
- 1992-03-12 WO PCT/US1992/002043 patent/WO1992016181A2/en active IP Right Grant
- 1992-03-12 EP EP92908042A patent/EP0575484B1/en not_active Expired - Lifetime
- 1992-03-12 AU AU15591/92A patent/AU656372B2/en not_active Ceased
- 1992-03-12 CA CA002106073A patent/CA2106073C/en not_active Expired - Fee Related
- 1992-03-12 US US07/849,931 patent/US5376636A/en not_active Expired - Fee Related
- 1992-03-12 DE DE69231486T patent/DE69231486T2/en not_active Expired - Fee Related
- 1992-03-12 JP JP4507585A patent/JPH07505858A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0134385A2 (en) * | 1983-06-30 | 1985-03-20 | Sanwa Kagaku Kenkyusho Co., Ltd. | A protein having cell growth stimulating action, composition thereof and method for producing the same |
WO1988004180A1 (en) * | 1986-12-11 | 1988-06-16 | National Research Development Corporation | Improvements in or relating to the use of epidermal growth factor |
Non-Patent Citations (5)
Title |
---|
Biological Abstracts, vol. 86, nr. 3, 1988, abstract nr. 24434, Philadelphia, PA, Us, Phillips, Paul D. & Vincent J. Cristofalo "Classification system based on the functional equivalency of mitogens that regulate WI-38 cell proliferation" * |
CHEMICAL ABSTRACTS, vol. 101, no. 9, 27 August 1984, Columbus, Ohio, US; abstract no. 66333, SYMS ET AL.: 'Autocrine regulation of growth: Glucocorticoid regulation is overcome by exogenous platelet derived growth factor' page 90 ;column 2 ; * |
CHEMICAL ABSTRACTS, vol. 110, no. 23, 5 June 1989, Columbus, Ohio, US; abstract no. 206533, PIERCE ET AL.: 'Transforming growth factor beta reverses the glucocorticoid-induced wound-healing deficit in rats: possible regulation in macrophage by platelet-derived growth factor' page 161 ;column 2 ; * |
CHEMICAL ABSTRACTS, vol. 89, no. 15, 9 October 1978, Columbus, Ohio, US; abstract no. 123469, CHEUNG ET AL.: 'Independent effects of human platelet growth factor and hydrocortisone on acetate incorporation by GM-237 human fibroplast' page 79 ;column 1 ; * |
See also references of EP0575484A1 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997045533A1 (en) * | 1996-05-28 | 1997-12-04 | The Regents Of The University Of Michigan | Engineering oral tissues |
US5885829A (en) * | 1996-05-28 | 1999-03-23 | The Regents Of The University Of Michigan | Engineering oral tissues |
US7847087B2 (en) | 2001-03-05 | 2010-12-07 | Siemens Healthcare Diagnostics Inc. | Methods and primers for evaluating HIV-1 mutations |
WO2003037356A1 (en) * | 2001-10-26 | 2003-05-08 | Fresenius Kabi Deutschland Gmbh | Pharmaceutical preparation comprising a growth factor and/or a cytokine and an antiseptic biguanide |
US9545377B2 (en) | 2004-10-14 | 2017-01-17 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
US11318230B2 (en) | 2004-10-14 | 2022-05-03 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
US10258566B2 (en) | 2004-10-14 | 2019-04-16 | Biomimetic Therapeutics, Llc | Compositions and methods for treating bone |
US11571497B2 (en) | 2004-10-14 | 2023-02-07 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
US11364325B2 (en) | 2004-10-14 | 2022-06-21 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
US9642891B2 (en) | 2006-06-30 | 2017-05-09 | Biomimetic Therapeutics, Llc | Compositions and methods for treating rotator cuff injuries |
US10456450B2 (en) | 2006-06-30 | 2019-10-29 | Biomimetic Therapeutics, Llc | Compositions and methods for treating rotator cuff injuries |
US11058801B2 (en) | 2006-06-30 | 2021-07-13 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
US8870954B2 (en) | 2008-09-09 | 2014-10-28 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
US11135341B2 (en) | 2008-09-09 | 2021-10-05 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor composition and methods for the treatment of tendon and ligament injuries |
US11235030B2 (en) | 2010-02-22 | 2022-02-01 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
Also Published As
Publication number | Publication date |
---|---|
DE69231486T2 (en) | 2001-04-26 |
ATE196604T1 (en) | 2000-10-15 |
CA2106073C (en) | 2003-09-30 |
EP0575484B1 (en) | 2000-09-27 |
EP0575484A1 (en) | 1993-12-29 |
CA2106073A1 (en) | 1993-09-13 |
AU1559192A (en) | 1992-10-21 |
WO1992016181A3 (en) | 1992-11-12 |
US5376636A (en) | 1994-12-27 |
US5149691A (en) | 1992-09-22 |
JPH07505858A (en) | 1995-06-29 |
AU656372B2 (en) | 1995-02-02 |
DE69231486D1 (en) | 2000-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU656372B2 (en) | Composition for promoting tissue repair and regeneration | |
US6287606B1 (en) | Methods of enhancing wound healing and tissue repair | |
Saito et al. | Bone‐resorbing activity and prostaglandin E produced by human periodontal ligament cells in vitro | |
CA2105997A1 (en) | Method of inhibiting padgem-mediated interactions using an inhibitor comprising a 2,6 sialic acid component | |
Oates et al. | Mitogenic effects of growth factors on human periodontal ligament cells in vitro | |
GLOBUS et al. | Regulation of bovine bone cell proliferation by fibroblast growth factor and transforming growth factorβ | |
EP0679097B1 (en) | Tgf-beta formulation for inducing bone growth | |
US6649168B2 (en) | Pharmaceutical compositions comprising TGF-beta | |
RU2140282C1 (en) | Composition stimulating growth of osteoblasts and containing and vitamin d | |
JP2001506635A (en) | Compositions and methods for stimulating bone growth | |
JPH01121300A (en) | Polypeptide growth factor occurring from milk | |
JPH06511233A (en) | Bone growth factors and bone resorption inhibitors to promote bone formation | |
US8513191B2 (en) | Therapeutic agent and therapeutic method for periodontal diseases and pulpal diseases | |
Gamal et al. | The effect of local delivery of PDGF‐BB on attachment of human periodontal ligament fibroblasts to periodontitis‐affected root surfaces–in vitro | |
JP3395904B2 (en) | Methods for enhancing wound healing and tissue repair | |
AU621368B2 (en) | Pharmaceutical composition containing deoxyribonucleosides and/or deoxyribonucleotides for wound healing | |
EP0531425B1 (en) | Combination of IGF-I and TGF-beta for bone regeneration | |
US20050142076A1 (en) | Dental viscous pharmaceutical containing basic fibroblast growth factor | |
JPH07504160A (en) | bone regeneration | |
Mailhot et al. | Porous Polysulfone Coated With Platelet‐Derived Growth Factor‐BB Stimulates Proliferation of Human Periodontal Ligament Fibroblasts | |
JPH07316066A (en) | Wound healing agent | |
US5246700A (en) | Pharmaceutical compositions for treating bone disorders | |
JPH03502922A (en) | Local wound treatment formulation containing interleukin-1 protein | |
Ksander et al. | Exogenous transforming growth factor‐β2 enhances connective tissue formation in transforming growth factor‐β1—deficient, healing‐impaired dermal wounds in mice | |
JPH10231251A (en) | Medicine for promoting regeneration of periodontal tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
CFP | Corrected version of a pamphlet front page |
Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2106073 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992908042 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992908042 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992908042 Country of ref document: EP |